Sign in
4

Changes in Ownership

Obsidian Therapeutics, Inc. Filed Acc 0001193125-26-335082

Options or other derivatives

  • Chief Executive Officer acquired 37,653 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Jagasia Madan · Chief Executive Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-08-03 Grant or award : show line 1 in the form Stock Option (Right to Buy) +37,653 37,653 D
Loading xslF345X06/ownership.xml…